Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

By J. Keane, S. Gershon, R. Wise, E. Mirabile-Levens, J. Kasznica, W. Schwieterman, J. Siegel, M. Braun. New England Journal of Medicine, 2001

2,029 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Surgery

View Paper: https://www.semanticscholar.org/paper/026196b19c18e27d8ae7dd859d91da554a9ed1d2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. O’Garra
2. R. Wilkinson
3. M. Berry
4. Finlay W Mcnab
5. Paul S. Redford
6. C. Bloom
7. F. Balkwill

In Infectious Diseases

1. A. O’Garra
2. R. Wilkinson
3. M. Berry
4. Finlay W Mcnab
5. Paul S. Redford
6. C. Bloom

In Surgery

1. A. O’Garra
2. R. Wilkinson
3. M. Berry
4. Finlay W Mcnab
5. Paul S. Redford
6. C. Bloom

Citations in the corpus

• Granulomatous infectious diseases associated with tumor necrosis factor antagonists. (2004, result): “Previous reports have suggested that these infections were particularly associated with infliximab rather than etanercept [4, 7]; however, the small numbers of cases reported in these series limited the statistical power of such observations.”
• Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. (2003, background): “clinical trials, a recent report (4) on the relationship”
• Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. (2005, background): “5 per 100,000 patient-years among those patients followed up prospectively (1,5).”
• TNF-α in promotion and progression of cancer (2006, background): “Although there is good evidence from experimental cancer studies that TNF-α can act as an endogenous tumour promoter at an early stage of disease, increased susceptibility to opportunistic infections such as Mycobacterium tuberculosis in patients taking TNF-α antagonists [61, 62], would preclude wid”
• Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. (2006, background): “Further, use of anti–TNF- therapies has been associated with increased risk of tuberculosis infection and reactivation (46).”
• Epidemiology of extrapulmonary tuberculosis in the United States, 1993-2006. (2009, result): “Some authors have identified a higher frequency of EPTB, compared with the frequency of PTB, among patients on particular immunosuppressive therapies [36] or have advocated increased suspicion of EPTB in rheumatologic patients [37].”
• Binding and functional comparisons of two types of tumor necrosis factor antagonists. (2002, background): “…important distinctions in the safety profiles of these two products, most notably an increased risk of specific types of infection for infliximab (Keane et al., 2001) or etanercept (Fisher et al., 1996; Song et al., 2001), or possibly an increased risk of neurological disorders for etanercept…”